125 products were found matching "K01313"!

PPACK is a synthetic peptide derivative that irreversibly and specifically inhibits thrombin-mediated platelet activation by binding with high affinity to the active site of thrombin (Ki = 0.24 nM). It has been used as an anticoagulant (100 µM) and to study thrombin-mediated fibrin deposition, angiogenesis, and...

(BOC-VPR)2R110 is a sentive fluorogenic substrate for alpha-thrombin. The non-fluorescent substrate generates a bright green fluorescent R110 product that has Ex/Em = 495/520 nm, and can be easily detected with the FITC filter set. This substrate has also been used for the rapid detection of MRSA...

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), also known as Des-gamma-carboxy-prothrombin (DCP), is an abnormal form of prothrombin. Normally, the prothrombin's 10 glutamic acid residues (Glu) in the gamma-carboxyglutamic acid (Gla) domain at positions 6, 7, 14, 16, 19, 20,25, 26, 29 and 32 are...

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), also known as Des-gamma-carboxy-prothrombin (DCP), is an abnormal form of prothrombin. Normally, the prothrombin's 10 glutamic acid residues (Glu) in the gamma-carboxyglutamic acid (Gla) domain at positions 6, 7, 14, 16, 19, 20,25, 26, 29 and 32 are...

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), also known as Des-gamma-carboxy-prothrombin (DCP), is an abnormal form of prothrombin. Normally, the prothrombin's 10 glutamic acid residues (Glu) in the gamma-carboxyglutamic acid (Gla) domain at positions 6, 7, 14, 16, 19, 20,25, 26, 29 and 32 are...

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), also known as Des-gamma-carboxy-prothrombin (DCP), is an abnormal form of prothrombin. Normally, the prothrombin's 10 glutamic acid residues (Glu) in the gamma-carboxyglutamic acid (Gla) domain at positions 6, 7, 14, 16, 19, 20,25, 26, 29 and 32 are...

Dabigatran acyl-beta-D-glucuronide is an active metabolite of the thrombin inhibitor dabigatran (Cay17133). It is formed from dabigatran primarily by the UDP-glucuronosyltransferase (UGT) isoform UGT2B15. Dabigatran acyl-beta-D-glucuronide (0.46 µM) increases activated partial thromboplastin time (aPTT) in isolated...

Dabigatran etexilate is a prodrug form of the thrombin inhibitor dabigatran (Cay-17133). It inhibits thrombin-induced platelet aggregation in isolated rabbit platelets (IC50 = 0.337 µM) and inhibits thrombus formation in a rat model of venous thrombosis (ED50 = 7.8 µmol/kg). Formulations containing dabigatran...

Melagatran is an inhibitor of thrombin (Ki = 0. µM) and an active metabolite of the prodrug ximelagatran (Cay-16862). It is selective for thrombin over a variety of serine proteases (Kis = 0.6-10. µM) but also inhibits trypsin (Ki = 0. µM). Melagatran inhibits thrombin-induced aggregation of isolated washed human...

Dabigatran is an inhibitor of thrombin (Ki = 0.0045 µM) and an active metabolite of the thrombin inhibitor prodrug dabigatran etexilate (Cay-17131). It also inhibits trypsin (Ki = 0.0503 µM) but is selective for thrombin and trypsin over plasmin, Factor Xa, activated protein C, and tissue plasminogen activator (tPA,...

p-APMSF is an irreversible inhibitor of serine proteases with Ki values of 1.02, 1.18, 1.5, and 1.54 µM for bovine trypsin, human thrombin, bovine plasmin, and bovine Factor Xa, respectively. It is selective for these proteases over bovine chymotrypsin and acetylcholinesterase.Formal Name:...

Description: Dabigatran (BIBR 953ZW) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. Target: Thrombin. Smiles:...